Skip to main content

Ester Palacio Gutierrez

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca

Ester Palacio Gutierrez

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

NANOPARTICULAS BIODEGRADABLES DE SIMVASTATINA COMO NUEVA HERRAMIENTA TERAPÉUTICA PARA LA ENFERMEDAD HEPÁTICA CRÓNICA

IP: Maria Nieves Martell Pérez-Alcalde
Collaborators: Immaculada Raurell Saborit, Ester Palacio Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI17/00754
Duration: 01/01/2018 - 31/12/2020

LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

IP: -
Collaborators: Ester Palacio Gutierrez, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer
Funding agency: EUROPEAN COMMISSION
Funding: 409557
Reference: LIVERHOPE_H2020RTD2016
Duration: 01/01/2017 - 28/02/2023

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Maria Antonia Ramon Belmonte

Maria Antonia Ramon Belmonte

Senior researcher
Pneumology
Read more
Rebeca Martinez Ordinas

Rebeca Martinez Ordinas

Administrative
Purchase and Biddings Unit
Finance Directorate
Read more
Ana  Román Mora

Ana Román Mora

Secretary
Communication Unit
Communication Directorate
Read more
Anna Marcé Grau

Anna Marcé Grau

Main researcher
Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.